Chimerix announced final data from CMX001 Study 201, a Phase 2 study evaluating CMX001 for the prevention of cytomegalovirus in hematopoietic cell transplant recipients.
CMX001 Study 201 was a randomized, placebo-controlled study. Two hundred thirty subjects were randomized (3:1) to receive CMX001 or placebo in five sequential, dose-escalating cohorts. Subjects were dosed either once weekly or twice weekly for 9–11 weeks until post-transplant week 13, with a 4–8 week follow-up period.
CMX001 is a broad spectrum, Lipid-Antiviral-Conjugate that delivers high intracellular levels of the active antiviral agent cidofovir-diphosphate and has broad spectrum activity against dsDNA viruses.
For additional information call (919) 806-1074 or visit http://www.chimerix.com/.